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mISTORICAL MILESTONES
n September 16, 1977, the first successful angioplasty was
erformed by Andreas Gruentzig. Ten years later, the
atient underwent recatheterization, which showed that the
reviously instrumented coronary artery was widely patent
1). The year 1986 marked the beginning of the stent era,
ith the first implantation of the self-expanding Wallstent by
lrich Sigwart in Lausanne (2). In 1994, the results from Stent
estenosis Study (STRESS) investigators (3) and the Bene-
tent Study Group (4) became available. The Belgium Neth-
rlands Stent Arterial Revascularization Therapies Study
BENESTENT)-1 demonstrated that the implantation of
etallic stents results in a reduction in the restenosis rate
rom 32% to 22%. Similarly, the occurrence of any adverse
vent at seven months was reduced from 29.6% to 20.1%.
July 1999 was a fresh new start for me. I had been invited
o the headquarters of Cordis Corporation in Warren, New
ersey, where I was introduced to a rapamycin-eluting stent
nd asked how to begin a Phase II program for it. I was
mpressed by the molecular biology behind the principles:
irolimus (which is attached to the internal receptor,
KBP12), by acting on mTOR, influences the up-regulation
nd down-regulation of p27 and, therefore, blocks cell
roliferation. The original plan of the first-in-human study
as to conduct the trial in a country outside the U.S., with
afety monitoring (i.e., subacute thrombosis, myocardial
nfarction, death) for 60 days, and to treat these patients for
0 days with ticlopidine and aspirin. After discussion, the
nal plan was made to perform quantitative coronary
ngiography and quantitative intravascular ultrasound
IVUS) motorized pullback in 15 patients in Rotterdam and
0 patients in Sao Paulo (5,6). It was a happy time,
ommuting between Amsterdam and Sao Paulo on KLM
ight 797. One day we succeeded in performing 15 consec-
tive angiographic and IVUS follow-up studies, with a
ebriefing at the end of the day. At the end of that
emorable day, a bottle of champagne was opened to
elebrate the end of an iatrogenic disease: restenosis by
ntrastent neointimal hyperplasia. The holy grail of 25 years
f fighting against restenosis was completed.
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.a
Manuscript received August 16, 2005; revised manuscript received December 15,
005, accepted December 21, 2005.At the Andreas Gruentzig Lecture of the ESC Congress
n September 2000, presenting these results, I begged the
udience by telling them, “Don’t wake me up. Don’t pinch
e. Let me keep dreaming,” because at that time we had the
ngiographic control of the first 45 patients showing the
bsence of late loss, restenosis, and target vessel revascular-
zation (7). At the same meeting in September 2000, I
resented my vision of the future, the so-called rosy proph-
cy (Fig. 1). The Coronary Angioplasty versus Bypass
evascularization Investigation (CABRI) trial, which was
onducted in the early 1990s and compared balloon angio-
lasty and bypass surgery, showed a gap of 32% in clinical
utcome between the two methods of revascularization. In
999, the gap between the outcome of surgery and the
utcome of the percutaneous treatment was reduced to 14%
n the Arterial Revascularization Therapies Study (ARTS)
rial (8). My rosy prophecy predicted that in the future the
aplan-Meier estimate of freedom from major adverse
vents with eluting stents would be even greater that of
urgery, which was, and still remains, quite a provocative
tatement.
In those days, The Wall Street Journal interviewed me. I
aid to the journalists that “we are not talking about some
ind of reduction of restenosis. We are talking about the
adical abolition of what we normally see. There is basically
o tissue visible in the stent.” In another very “scientific”
ublication, The New York Times, Dr. Spencer King, III,
aid that “he was encouraged by the early findings, but
ished cardiologists would tone down the rhetoric a little.
nd that the pilot trials cry out for larger and more rigorously
esigned studies known as randomized double-blind placebo-
ontrolled trials to provide definitive answers.”
The Randomized Study with the Sirolimus-Coated Bx
elocity (RAVEL) trial, presented by Marie-Claude Mor-
ce at the European Society of Cardiology Congress of
001, showed a zero late-loss, a zero restenosis rate, a target
esion revascularization percentage of zero, and an astonish-
ng 97% event-free survival. In 2002, we published the
eport in the New England Journal of Medicine: this was the
eal beginning of the drug-eluting stent era (9). To date,
any trials with sirolimus and paclitaxel have confirmed
hese first observations (10–15). In all these trials, a treat-
ent effect of approximately 70% to 80% exists: the events
t 6 and 12 months are less than the two digits for the
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ow? In this lecture, I will review the future of interven-
ional cardiology.
RUG-ELUTING STENTS
here are we heading to? Let’s start analyzing what can
e expected beyond the published randomized trials on
rug-eluting stents. The drug-eluting stent revolution has
shered into clinical practice. In Rotterdam, since April
002, the implantation of drug-eluting stents has been the
efault strategy for all patients treated using percutaneous
oronary intervention (PCI) in our daily practice, which
eans more than 3,700 patients and more than 8,000
luting stents (14,15). In addition, we have shown that there
s a 66% relative reduction in the need for clinically driven
arget vessel revascularization, from 13.9% to 4.8%, which is
major achievement, indeed! We have scrutinized the
apamycin-Eluting Stent Evaluated At Rotterdam Cardi-
logy Hospital (RESEARCH) registry quite intensively, I
ould say, which has resulted in a large number of publi-
ations in well-known peer-reviewed journals. We have
ummarized our experience in a monograph entitled “From
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CT  computed tomography
CTO  chronic tomography occlusion
EEM  external elastic membrane
EPC  endothelial progenitor cell
IVUS  intravascular ultrasound
MACE  major adverse cardiac event
MI  myocardial infarction
MRI  magnetic resonance imaging
OCT  optical coherence tomography
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplasty
TCFA  thin-cap fibroatheromaigure 1. The rosy prophecy. ARTS  Arterial Revascularization Therapies
ngioplasty versus Bypass Revascularization Investigation; MI  myocardial inESEARCH to Clinical Practice” (16). We documented a
ystematic treatment effect in reducing reintervention from
0% to 80% in the global population, which also holds true
n specific subsets of patients, such as those with acute MI,
enal failure, previous bypass surgery, chronic total occlu-
ions, very long lesions, in those undergoing bifurcation
tenting, or in those receiving undersized stents, to treat
n-stent restenosis, mild stenosis, very small vessels, main-
tem stenting, or multivessel stenting.
I would like to draw your attention to the main-stem
ubgroup with a restenosis rate of 8% (17) and the mul-
ivessel stented subgroup with a major adverse cardiac event
MACE) rate of 14%, which is not far away from the
ACE rate of 11% observed in ARTS-I after surgery (8).
e have published a meta-analysis of Stent or Surgery
SoS), Argentine Randomized Trial of Coronary Stents
ersus Bypass Surgery in Multivessel Disease (ERACI), and
RTS, which indicates that the cumulative incidence of
eath, nonfatal myocardial infarction (MI), stroke, and
epeat revascularization (18) is 13% in the bypass group: I
annot resist the temptation to compare our current MACE
are in multivessel eluting stenting (i.e., 14%) with the
umulative event rate observed in the surgical arm of the
eta-analysis (i.e., 13%).
Recently, we reported the results of ARTS-II as com-
ared with the surgical and PCI arm of ARTS-I (19,20).
espite the fact that we had a majority of three-vessel
isease and despite the fact that an average of 3.2 lesions
ere stented using 3.7 stents, with a total average stent
ength of 73 mm (compared with 48 mm in ARTS-I),
reedom from death, stroke, MI, coronary artery bypass
rafting, and re-percutaneous transluminal coronary angio-
lasty curve was 89.5%. Figure 1 shows the Kaplan-Meier
urve of ARTS-II: it is well above the surgical arm of
RTS-I and the PCI arm of ARTS-I. Therefore, the rosy
rophecy has come true.Study; CABG  coronary artery bypass graft; CABRI  Coronary
farction; PTCA  percutaneous transluminal coronary angioplasty.
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Fourth Annual ACC International Lecture May 2, 2006:1754–68The next logical step is to confirm these results in a
andomized trial. We set up the SYNergy between Percu-
aneous Coronary Intervention with TAXus and Cardiac
urgery (SYNTAX) trial for this purpose (21). In this study,
e are going to define the most appropriate treatment
coronary artery surgery vs. drug-eluting stents) through a
andomized approach. Around this randomized arm, two
egistries will be nested, coronary artery bypass grafting
CABG) with 2,750 patients and a PCI registry, to profile
large pool of nonrandomized patients and their subsequent
utcomes. Thus, we will address three-vessel diseased and
eft main diseased all-comers. Valentin Fuster is the chair-
an of the Future Revascularization Evaluation in Patients
ith Diabetes Mellitus: Optimal Management of Multives-
el Disease (FREEDOM) trial, which exclusively is enroll-
ng patients with diabetes mellitus and two- or three-vessel
isease. The structure of the FREEDOM trial is very similar
o SYNTAX, with a randomized arm and registries including
atients who can only be treated by bypass surgery or by PCI.
ndoubtedly, these two trials will impact on the strategy of
evascularization of our coronary artery disease patients in the
uture.
eyond conventional drug-eluting stents. The Conor is a
tent with multiple laser-drilled holes in the struts, which
erves as wells for drugs (22). They are filled with a fully
esorbable polymer and can elute drugs in two directions:
oward the lumen, but also in the direction of the vessel
all. Using paclitaxel, we have investigated six kinetic
rofiles (23). The two doses with long-lasting elution—10
r 30 g over 30 days resulted in the best outcome. A
rolonged elution, not necessarily of the highest dose,
roved to be crucial to induce a drastic reduction of
eointimal volume, late-loss, obstruction volume, and bi-
ary restenosis. But my interest in this stent is not so much
he prevention of restenosis. For me, it is a conceptually new
nstrument in our interventional armamentarium because of
he bidirectional elution; we can now elute drugs into the
umen of the vessel for specific purposes. Among the first
argets that we would like to address is the treatment of
cute MI: the industry has created a stent delivering insulin
o the infracted region attempting at accelerating and
mproving myocardial recovery. Insulin increases the glyco-
ytic metabolism and the generation of adenosine triphos-
hate in ischemic cells, decreases the transcellular flux of
ree-fatty acids, and stimulates growth factors, which may
ell translate in clinical benefits.
The Yukon stent is what we call a customized stent. The
urface of a stent is usually very smooth, through electropol-
shing treatment. At variance with the conventional stent,
he surface of the Yukon stent is very porous to absorb the
rug in the superficial layers of the metal. Therefore, the
perator can load the drug of his or her choice on the surface
f this stent. Dr. Kastrati recently has reported the results
btained with increasing doses of rapamycin, from 0.5% to
%; there is a decrease in late lumen loss and restenosis rate s24,25). It’s, thus, a kind of customized “homemade” eluting
tent.
Endothelial progenitor cell (EPC) capture stent coating is
nother fascinating concept (26). The principle is to coat the
urface of the stent with monoclonal antibodies against
D34. CD34, a well-known marker of staminality, is one of
he antigens at the surface of the human progenitor cell.
he idea behind this technology is to capture these EPCs to
over the luminal surface of the entire stent, accelerating the
tent endothelialization. The EPCs, once captured by the
onoclonal antibody on the surface of the stent, have a
endency to flatten, to converge, and to grow rapidly within
ours. Figure 2A shows a bare stent explanted after one
our; on scanning electron microscopy they have maybe 50
ells, potentially EPCs, attached on the surface of the stent.
n a stent coated with the monoclonal antibody against
D34 (Fig. 2B), there is great abundance of cells on the
truts; therefore, it is not surprising to see that 48 hours later
he struts, and also the surface between the struts, are
ntirely covered by these endothelial cells, with very few
aps. It is amazing to see that these cells are oriented in
he direction of the flow already few hours after stent
mplantation.
Two human trials are currently in progress correlating the
umber of CD34, KDR-positive cells in the circulating
lood with the reduction in intrastent neointimal volume at
ix months to document the antirestenosis effect of these
D34 capture stents. This demonstration is the first of a
uccessful technique for the endothelialization of an intra-
ascular device by in vivo capture of autologous endothelial
ells.
In recent animal work, some investigators have used a
aked plasmid deoxyribonucleic acid-eluting stent encoding
or human vascular endothelial growth factor-2 to promote
e-endothelialization (27). A clear reduction of neointimal
yperplasia was demonstrated and undoubtedly the quality
f the endothelium, analyzed by silver staining or scanning
lectron microscopy, was superior in the treated group when
ompared with placebo.
The c-myc antisense-eluting stent is another attempt at
educing the intrastent neointimal hyperplasia (28). Anti-
igure 2. Endothelial progenitor cell capture stent. (A) Bare stent;
B) coated stent.ense is a complimentary sequence of deoxyribonucleic acid,
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May 2, 2006:1754–68 Fourth Annual ACC International Lecturef ribonucleic acid, created to block the sense of the genetic
ode (therefore, the name antisense) thereby preventing
roliferation by blocking messenger ribonucleic acid. There
re 10 different antisense compounds under investigation
nd, very recently, Dr. Kipshidze has reported quite encour-
ging results on stent eluting antisense, against, c-myc, in a
orcine model.
Nitric oxide-eluting stent is another novelty. The stretch
f an artery induces contraction and spasm; concomitantly
here is some signaling message triggering smooth muscle
ell migration; the endothelial cells are removed, thereby
ecreasing the natural healing process; platelet aggregation
nd smooth muscle cell proliferation occur (Fig. 3). Nitric
xide can theoretically block all these reactions. What is
ascinating is that today we have a polymer (polyethylenei-
ine) on which we can load highly pure nitric oxide under
igh pressure and, upon contact with physiological liquid
ontaining hydrogen, pure nitric oxide is released. In addi-
ion, nanoelectrospin technology was used to create very tiny
icrofilaments of this polymer that can be pulverized on the
urface of the balloon or on the surface of a stent. This
rocess creates a three-dimensional adhesion matrix con-
aining nitric oxide that awaits release by interaction with
ydrogen molecules.
A new generation of bioabsorbable stents has emerged.
mong them is a stent made of tyrosine-derived poly-DTE
arbonate that has many interesting properties. It is com-
letely reabsorbable; second, it has scaffolding properties
omparable with steel; third, it can be deployed by a
tandard balloon and, finally, it is inherently radio-opaque
ut compatible with magnetic resonance imaging (MRI)
Figure 3. (A) Normal mechanism of vessel stress; (B) effecnd can be loaded with drugs. The deployment of this aesorbable stent is not achieved by stretching the polymer
uring the deployment but by using a lock-out mechanism
ith sliding parts.
A bioabsorbable metal stent made from magnesium is
otentially another phenomenal development (29). Basi-
ally, certain magnesium alloys placed in a 0.9% sodium
hloride solution at 37°C, pH 7, will melt and progressively
issolve. Various dissolution kinetics are feasible and de-
ending on the alloy, you can dissolve this stent in 60 days
ut you can also dissolve in fewer than 5 days, depending on
he composition of magnesium with the other oligo-
lements. It is an interesting concept because the stents are
RI compatible. It is seems that in animals it does not
reclude positive remodeling. In pigs, the stents are barely
isible at 30 days and the metal has disappeared with only
ome remnants of the stent. These stents have been im-
lanted in human coronary arteries and in peripheral vessels.
As for bioabsorbable drug-eluting stents, one version of
hese stents has been published in the European Heart Jour-
al (30). The stent is loaded with paclitaxel. Complete
xpansion of the stent is reached at 6-bar insufflation. The
adial strength resists an outside pressure of 0.5 bar, without
elevant diameter shrinkage. The histomorphometric anal-
sis of this stent at three weeks shows remnants of the
olymer, but at three months the presence of the polymer
tent is no longer detected; the eluting paclitaxel stent shows
larger lumen with a reduction in neointimal area when
ompared with the noneluting version.
Thus, during the last 20 years, the technology has evolved
rom balloon to mechanical ablation, atherectomy, stenting,
device eluting nitric oxide. SMC  smooth muscle cell.nd radiation to the current technology, focused on drug-
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bsorbable stents, and gene modifiers (Fig. 4).
ULNERABLE PLAQUE
he vulnerable plaque is potentially a new target for the
nterventional cardiologist. The classic vulnerable plaque is
he so-called thin-cap fibroatheroma (TCFA), which stands
or the thin-cap fibroatheroma, defined by a large necrotic
ipid core beneath a thin fibrous cap. There exists other
ulnerable plaques; the one that is prone to erosion without
necrotic lipid pool, that lacks a thin fibrous cap, and that
s prone to inflammation; one that is characterized by
isruptive calcified nodules in the fibrous cap; and the
ulnerable plaque characterized by intraplaque hemorrhage
ikely because of leakage of vasa vasorum in the adventitia.
We are entering into a new diagnostic world (Fig. 5). In
n individual with a single episode of chest pain and with
igh levels of biomarkers, it is tempting to look noninva-
ively at his/her coronary arteries with a multislice computed
omography (CT) scan and see whether this high-risk
ndividual has a large plaque burden and is at risk in the near
uture. Figure 6A is a right coronary artery on angiography,
ith an equivalent angiographic view on a multislice CT
can (Fig. 6B). A small nucleus of calcium is identified; on
cross section of this vessel (Fig. 6C), we see clearly the
umen of the vessel, filled by contrast medium, and the
alcium in the vessel wall (Fig. 6D). An IVUS was per-
ormed in this patient, which showed at the same site the
chocardiographic shadowing due to calcium (Fig. 6E).
During the last two years, we (31) and others have
ttempted to correlate the plaque characteristics observed on
VUS to with those detected by multislice CT; we have
ivided plaques in small, medium, and large and defined the
espective Hounsfield units of these plaques and we have
nvestigated the sensitivity and specificity of the relationship
etween the multislice CT-defined plaque and the IVUS-
onfirmed plaque, defined as an external elastic membrane
EEM) obstruction greater than 50% or the presence of
alcium. Today, the sensitivity and specificity are 74% and
3%, respectively. The number of plaques you can find in a
igure 4. Where we have come from and where we are going: the next
nnovative steps in vascular intervention.ingle individual is impressive: plaque growth is a ubiquitoushenomenon, with some clustering in the proximal seg-
ents of the major epicardial vessels (Fig. 7).
The question for the cardiologist is not whether, but
hen will noninvasive imaging definitively serve in a triage
unction? In a symptomatic, flow-limiting lesion, at what
evel of diagnostic precision (64, 128 slices) will we decide to
end directly the patient either to surgery or PCI, based on
his diagnostic information? The problem is really what we
re going to do with the non–flow-limiting lesion. What do
e do with the asymptomatic non–flow-limiting potentially
ulnerable plaque that is detected accidentally on a multi-
lice CT scan?
Another outstanding issue we have to give an answer to is
hat can we expect from biomarkers? Biomarkers, such as
-reactive protein, interleukin-6, B-type natriuretic pep-
ide, and Lp-PLA2, are in our experience quite useful, to
ifferentiate a patient who had just an acute MI or who are
nstable, from those who are stable. Discrimination based
n a biomarker is possible. However, recently in a small
ohort of 85 patients, we performed a proteomic analysis of
lasma, in which we determined up to 78 analytes. It
ppears that the clustering of these numerous biomarkers
oes not seem to predict the imminence of an acute event.
sing hierarchical clustering statistics, we tried to find a
luster of biomarkers, potentially indicative of unstable
ngina, pre-MI, or stable angina, but even assisted by this
ophisticated approach, we failed to identify relevant prog-
ostic markers.
Now, let us assume that we have an individual with a
ingle episode of chest pain with abnormal levels of biomar-
ers (including troponins) and non–flow-limiting plaque
ho is brought to the catheter laboratory for invasive assess-
ent.With that scenario, further assessment of this non–flow-
imiting lesion may become even more complicated because
ou may use a battery of tests to further characterize this
on-flow limiting lesion. We know that the four-
imensional IVUS (three-dimensional image dynamically
nalyzed in time) acquired with electrocardiographic gating
s very appealing and suggestive of early stage of plaque
upture. However, we must realize that the sensitivity and
he specificity of the grayscale IVUS in predicting plaque
upture are still totally unknown today.Figure 5. The “new diagnostic world” of the vulnerable plaque.
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May 2, 2006:1754–68 Fourth Annual ACC International Lecturealpography. Intravascular ultrasound palpography is a
echnique that has been developed by our bioengineering
roup in Rotterdam. It is basically an analysis of backscat-
ering of radiofrequency at two levels of blood pressure using
he stress of the blood pressure on the vessel wall to evaluate
he mechanical properties of the vessel, as if we could
palpate” the lumen from inside. On the color-coded scale
f strain, purple indicates a low-strain region which is hard,
tiff, and rigid, whereas yellow indicates a region of high
train that is soft, deformable, and therefore potentially
ragile and breakable.
igure 6. (A) Angiographic image of an intermediate lesion in the proxim
mage of the lesion (vertical view); (C) corresponding multislice computed
lacified plaque in panel C; and (E) corresponding intravascular ultrasonicigure 7. Multislice computed tomography (MSCT) plaque burden: an ubiquit
CA  left coronary artery; RCA  right coronary artery.We have demonstrated using ex vivo human coronary
rteries that the sensitivity and specificity of the palpogram
s high and that a region of high strain with a deformation
f more than 2% corresponds quite accurately to an accu-
ulation of macrophage and to a defect in smooth muscle
ell or collagen (32). Therefore, we are quite confident that
his technique in the near future will help us detecting
high-strain spots.” From a practical standpoint, the infor-
ation is obtained though a conventional IVUS pullback.
e were impressed recently with how many of these
igh-strain regions are identifiable in a single patients
ght coronary artery; (B) corresponding multislice computed tomographic
ographic image of the lesion (horizontal view); (D) enlarged view of the
e of the calcified plaque. AV  atrioventricular.al rious phenomenon. Results: distribution of any plaque-% (large plaque-%).
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Fourth Annual ACC International Lecture May 2, 2006:1754–68hroughout the coronary arteries. We have observed impor-
ant dynamic changes in palpography over a period of six
onths, particularly in patients with ST-segment elevation
yocardial infarction, who were statin naive at the start of
he clinical observation. We have created a classification
alled the ROtterdam Classification (ROC), dividing the
Figure 8. Diagnostic value of palpography. CRP  C
igure 9. Virtual histology or . . . how to convert an ex vivo (pressurized) i
ntravascular ultrasound cross section; (B) in vivo virtual histology color-coded o
encil sketch of ex vivo histology cross section.train in four subclasses of which the worst is ROC IV with
deformation 1.2% (33).
We have recently reported the following observations:
rst, that the number of high-strain spots rises in parallel
ith the level of C-reactive protein (33); second, that the
ensity of these high-strain spots is greater at presentation
ive protein; ROC  receiver-operating characteristic.
ascular ultrasound image into a color-coded histological cross section. (A)ntrav
f same cross section; (C) ex vivo histology of same cross section; (D) color
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May 2, 2006:1754–68 Fourth Annual ACC International Lecturen ST-segment elevation myocardial infarction than in
nstable, or stable patients; and third, that an aggressive
reatment using statins, angiotensin-converting enzyme in-
ibitors, clopidogrel, and aspirin can reduce, over a period of
ix months, the intensity and frequency of these high-strain
pots (Fig. 8).
irtual histology. Virtual histology is an attempt to char-
cterize tissue composition based also on the backscatter of
adiofrequency signals (34). A correlation between these
adiofrequency signals and histological structures of fresh
oronary arteries was statistically established. Virtual histol-
gy converts grayscale IVUS images into a color-coded
istological cross section using the following virtual histol-
gy legend: green, fibrous tissue; yellow, fibrofatty; white,
alcium; and red, lipid core. Renu Virmani, interested by
he concept of virtual histology, has tried to create a
ommon language between the virtual histology and the
rue histology. Figure 9 illustrates her attempt to correlate
irtual histology. According to her suggestion, a TCFA
ould be identified in virtual histology as a focal spot with a
ipid core of more than 10%, which is in direct contact with
he lumen (implying the absence of a thick fibrous cap of
ore than 200 to 400 m, the actual resolution of the
ltrasound technique) and associated with a percent area
bstruction of the EEM of more than 40% (35). Using this
VUS-derived definition of TCFA, we have recently estab-
ished the frequency of TCFA per centimeter of arteries in
atients with stable or unstable syndromes, in whom we
ound it more frequently. Optical coherence tomography
OCT) is the next diagnostic modality potentially useful in
he detection of TCFA. The imaging of this technique is
Figure 10. Optical coherence tomography showiased on the use of the backscatter of light by tissue. This cmaging technology has excellent resolution between 1 and
5 . Figure 10 shows the normal appearance of a vessel
ith an intima of 70  and a media of 130 , as well as the
nterface with the adventitia.
Excellent correlations between the thickness of the thin
aps on histological specimens and measurement by OCT
ave been published. Today we can identify in vivo a TCFA
esion (Fig. 11). The region with the thin fibrous cap can be
asily visualized; the tiny vessel that is joining the central
umen at the edge of this fibrous cap may be interconnected
ith the network of the vasa vasorum in the adventitia (Figs.
1B and 11C).
We are currently working on an attempt to combine the
maging of the cap with the assessment of its mechanical
roperties. To achieve that goal, we use a very compliant
alloon inflated at a low pressure of 200 mm Hg, which is
till physiological. Through the transparent polymer of the
alloon, the fibrous cap can be imaged whereas the elasto-
ram helps us to assess the mechanical properties of the
laque.
ntravascular MRI. The last tool for the detection of
ulnerable plaques is the intravascular MRI. In a fibrotic
tructure, molecules of water are free to move and do not
ffect substantially the decay of the magnetic resonance
ignal (blue signal) whereas in the mainly lipidic structures,
he free motion of the water is considerably impeded,
hereby slowing down the decay of the magnetic resonance
ignal (yellow signal). Therefore, this technique potentially
an differentiate a fibrous cap from a rich lipid core.
urrently, 122 patients have been investigated in a multi-
tailed three layer resolution of a coronary vessel.enter study in Europe.
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Fourth Annual ACC International Lecture May 2, 2006:1754–68Nonetheless, the major question is: What is the prognos-
ic value of all these diagnostic tools? Undoubtedly, their
rognostic value has to be established in longitudinal
tudies. However, as predicted by Peter Libby a few years
go, “If we could identify potentially unstable atheroma
efore they are evident, clinically we might even contem-
late angioplasty on non-significant stenosis to induce
mooth muscle cell proliferation and reinforce the plaque
brous cap” (36). At the present stage, we have not yet a
cheme of triaging vulnerable plaques. Asymptomatic high-
isk patients (by Framingham score) should be treated for
rimary prevention with systemic therapy (Fig. 12); how-
ver, if as the result of noninvasive imaging they are
Figure 11. (A) Optical coherence tomography showing thT
igure 12. Vulnerable plaque triage. CRP  C-reactive protein; DES 
rug-eluting stents; EEM  external elastic membrane.nvasively investigated, and we search for criteria of vulner-
bility in non–flow-limiting lesions proximal and focal with
n EEM obstruction 50%, positive remodeling, and large
ipid core in direct contact with the lumen on virtual
istology at the site of a high strain spot on palpography, the
linical temptation might be to treat these lesions with
rug-eluting stents.
HE LAST CORONARY FRONTIER:
HRONIC TOTAL OCCLUSION (CTO)
pening a CTO may confer to patients a significant
ve-year survival advantage compared with those in whom
he recanalization procedure failed. However, the success
ate of recanalization of CTOs is still low. Many new
echnologies are emerging but, so far, the only trial having
andomized conventional guide wires with a new technology
uch as the laser wire is the Total Occlusion with Angio-
lasty by using Laser guidewire (TOTAL), which showed
n overall success rate in both arms of 63.9%, which is quite
obering (37).
Therefore, what are the novelties in the field? The first is
laque digestion with collagenase (38). In an animal model
reated with collagenase, extensive plaque digestion occurs.
he external elastic membrane remains intact whereas the
brotic occlusion within the vessel is partially digested.
fibrous atheroma and (B and C) intramuscular capillary.here are other new devices, such as the Frontrunner, which
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May 2, 2006:1754–68 Fourth Annual ACC International Lectures a device using the principle of controlled blunt microdis-
ection to recanalize CTOs (39). Taking advantage of the
lastic properties of the adventitia versus the relative stiffness
f the fibrocalcific plaque to create fracture planes, the
evice has been used in clinical practice with some success.
ther devices use acoustic energy, which is designed to
reate microparticle fragments of 10  without harming
he surrounding healthy tissue. The “Crosser” device uses
iezoelectric crystals to convert alternative current into a
igh-frequency mechanical vibration at a frequency of 21
Hz, which is propagated to the tip of the catheter. This
ype of energy is not harmful to soft tissue but can easily
enetrate and cross a long piece of chalk in 3 to 5 min. It is
ompatible with a 6-F guide and a standard 0.014-inch
ire.
Another technique that is gaining ground is the so-called
ubintimal angioplasty. This is a technique used in a
ituation in which conventional transluminal techniques
lready have failed and have induced a subintimal dissection
40). When subintimal, the operator introduces an IVUS
atheter in which a small needle is incorporated that, under
ltrasonic imaging control, can be pointed toward the
umen of the vessel in the dissection space created between
he lumen and the adventitia. Then, the operator advances
his small needle, which is hollow, and pushes the needle
hrough a conventional wire, “wiring” the lesion outside the
laque and stenting the vessel. This approach works well in
he peripheral vessels and also has been applied to the
oronary artery as an investigational technique. The next
imple device consists of a catheter that can accommodate a
.014-inch wire (the Venture catheter; Veloicmed, Inc.,
aple Grove, Minnesota). The tip of the catheter can be
able 1. Phase II and III Angiogenesis Trials (Coronary Heart D
Trial Therapeutic Agent No. Patien
IVA Recombinant VEGF protein 178
IRST Recombinant FGF-2 protein 337
M-CSF Recombinant GM-CSF protein 21
GENT Adenovirus–FGF-4 79
GENT 2 Adenovirus–FGF-4 52
AT Adenovirus–VEGF165
Plasmid/liposome VEGF165
103
EVASC Adenovirus–VEGF121 67
uroinject One Plasmid VEGF165 74
eprinted, with permission, from Ylä-Herttuala et al. (41).
ETT  exercise tolerance test; FGF  fibroblast growth factor; GM-CSF  granul
ascular endothelial growth factor.
able 2. Skeletal Myoblast-Based Cell Therapy in Humans: Maj
First Author No. of Patients
Additional
Procedure
enasche (47) 10 CABG
agani (48) 5 LVAD
mits (49) 5 None
erreros (50) 12 CABG
iminiak (51) 10 CABGABG  coronary artery bypass grafting; LVAD  left ventricular assist device; NYHAeflected from straight up to 90 degrees by turning the knob
n a proximal handle.
Personally, I believe specific strategy is needed for CTOs
sing the following concepts: first, a nonmanual remote
teering of the wire, maybe through the use of magnetic
avigation; second: a technology to look forward, either
hrough the use of an optical coherence tomographic sys-
em, an optical low-coherence reflectometry system, or an
VUS system; finally, some ablative power is needed at the
ip of the wire to be able to recanalize these CTOs. At our
nstitution in Rotterdam, we have installed a magnetic
tereotactic system that we have been experimenting for
ore than one year. We are still exploring ways to use the
agnet to steer a guide wire in total chronic occlusions.
owever, in a 3-mm diameter vessel, exquisite control of
he tip of your guide wire can be achieved without guidance
r ablative power with the current state of the hardware.
The next step is to design a forward imaging technique.
or example, we have designed an OCT wire that can look
0° forward, so that the operator can see forward directly
nd accurately the interface between the media and the
dventitia. The concept is to have the target of the CTO
ontinuously in front of you (the cross section of the
ccluded vessel) as a circle (the interface between the media
nd the adventitia) (Fig. 13). The goal is to remain at the
enter of the target with your guide wire. In this scenario,
ou have guidance but not navigation capabilities or ablating
ower. Finally, we have currently at our disposal radiofre-
uency ablation techniques to ablate tissue. Therefore, the
nal dream on which we are working on is a combination of
looking-forward technique mounted on an ablating wire
hat can be steered by an external magnetic field.
e)
End Point Result
ETT (60 days) Negative
ETT (90 days) Negative
Invasive collateral flow index (2 weeks) Positive
ETT (4 weeks) Positive
MPI (8 weeks) Positive
MPI (6 months) Positive (adeno only)
ETT (time to 1-mm ST-segment
depression 26 weeks)
Negative
MPI (3 months) Negative
acrophage colony-stimulating factor; MPI  myocardial perfusion imaging; VEGF 
er-Reviewed Published Articles
hange in
HA Class
Change in Ejection
Fraction (%)
Follow-Up Period
(Months)
2.7–1.6 24–32 11
n.a. n.a. n.a.
n.a. 36–41 3
2.2–1.5 36–54 3
n.a. 36–42 4iseas
tsor Pe
C
NY New York Heart Association.
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able 1 (41) summarizes the studies that have been pub-
ished with some negative but also positive outcomes using
ither recombinant protein or an adenovirus, plasma lipo-
ome like in Angiogenic Gene Therapy (AGENT) (42) and
GENT-2 (43). What is disappointing is that the last
ajor clinical attempt to achieve some treatment effect with
ngiogenesis was the AGENT-3 trial. This trial was the
argest gene therapy trial so far; however in January of last
ear, enrollment was stopped because the interim data
nalysis indicated that the study would provide insufficient
vidence of efficacy. Mann et al. (44) are still working on a
enetic decoy approach specifically for the pretreatment of
ypass grafts before implantation; the preliminary results are
ncouraging.
A few words about cell transplantation (Tables 2 and 3).
he demonstration has been made that transplanted myo-
lasts or myotubes may stay “alive and kicking” in the
yocardium (45). The question that remains is whether the
echanical and electrical junction between the skeletal
yotube and the cardiomyocyte is effective and operational.
f course, in situations in which skeletal myoblasts are
ocultured with myocytes, the electromechanical coupling
orks because there is an up-regulation of the cadherin and
onnexin-43. However, in hosts, we do not have any proof
hat this up-regulation takes place in vivo (46). Neverthe-
ess, there are few published studies in major peer-review
ournals (47–51) suggesting that myoblast transplantation,
hich is associated with bypass surgery, results in some
odest increase in ejection fraction (47,50,51). However,
hese studies were monocenter investigations, not random-
igure 13. Phantom made of cryogel mimicking a total occlusion of which
ire (0.014 inch). OCT  optical coherence tomography.zed and without core laboratory assessment. In our patients mreated with intramyocardial injections of myoblasts, change
n left ventricular function, assessed by pressure volume loop
nalysis during volume unloading performed at 6 and 12
onths showed some encouraging results (52). We see, for
nstance, that the preload recruitable stroke work increases
ver time after treatment and that the end-systolic volume,
ormalized for a blood pressure of 120 mm Hg, is signifi-
antly decreased; together, some increase in ejection fraction
nd in dP/dT is noted; however, the end-systolic elasticity
nd the end-diastolic stiffness are not affected.
At the time of the publication, we were very puzzled by
he findings of the group from Houston on the transdiffer-
ntiation of human peripheral blood into cardiomyocytes,
ndothelial cells, and smooth muscle cells (53). Basically, in
heir experiment, they showed hat human peripheral cells
njected in immunotolerant mice with subacute MI were
pparently incorporated into the vessel wall and into the
yocardium. Shortly after this publication, Murry et al. (54)
eported in Nature that they could not confirm this trans-
ifferentiation into cardiomyocytes. They concluded that
heir results indicate that hematopoietic stem cells do not
eadily acquire a cardiac phenotype and raised a cautionary
ote for clinical studies on infarct repair. Other authors also
ave shown that wild-type bone marrow-derived stem cells
re indeed readily incorporated into cardiac muscle but that
hese cells fail to express sarcoglycan and thus are unable to
epair the tissue, suggesting that this stem cell population
as limited potential for cardiac cell or cardiac muscle
egeneration (55).
Table 3 summarizes the results of studies on acute MI
56–65). Most of these studies show some positive treat-
cross section is seen by a forward-looking (60°) optical coherence imagingent effects (increase in left ventricular ejection fraction,
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May 2, 2006:1754–68 Fourth Annual ACC International Lectureegmental wall motion, or myocardial perfusion or decrease
n infarct size or prevention of myocardial remodelling, and
o on) except for Autologous Stem Cell Transplantation in
cute Myocardial Infarction (ASTAMI) (63) and Regen-
rate Vital Myocardium by Vigorous Activation of Bone
arrow Stem Cells (REVIVAL-2) trials (65); in one study,
e even observed a deterioration in an infarct-related artery
ollowing the cell transplantation (occurrence of in-stent
eocclusion, in-stent restenosis, and significant de novo
esion) (60). In other words, may types of cells seem to
ork. However, when you examine the result of the first
andomized trial, BOne marrOw transfer to enhance ST-
levation infarct regeneration (BOOST) (59), it is amazing
o see that some difference in ejection fractions between the
wo groups was achieved, although there was no change in
nd-diastolic volume, end-systolic volume, left ventricular
ass, or late contrast enhancements on MRI. Furthermore,
he difference in ejection fraction was no longer significant
t 18 months.
Therefore, my personal view on cell therapy (sharing the
iews of Daniel Burkhoff) is that, with skeletal myoblasts
nd other cell types, engraftment and proliferation are
ossible. However, the techniques to achieve this result con-
able 3. Bone Marrow-Based Cell Therapy for Acute Myocardia
Trial
No. of Patients
and Donors
RCT or
Non-RCT
Po
Timi
trauer et al. (56) BMC 10 Non-RCT AMI w
Control 10
OPCARE-AMI
(57,58)
BMC 29 RCT STEM
4.9 
infar
CPC 30
OOST (59) BMC 30 RCT STEM
PCIControl 30
artunek et al. (60) CD133 BMC 19 Non-RCT AMI w
11.6
infar
Control 16
IRSTLINE-AMI
(61)
G-CSF 25 RCT STEM
89 
infarControl 25
EPAIR-AMI (62) BMC 101 RCT AMI w
3–6Control 103
STAMI (63) BMC 50 RCT AMI w
4–6Control 50
anssens et al. (64) BMC 33 RCT AMI 1
Control 34
EVIVAL-2 (65) G-CSF 56 RCT STEM
PCI
after
Control 58
MI  acute myocardial infarction; BMC  bone marrow cell; CPC  circulating b
entricular; LVEF left ventricular ejection fraction; MRImagnetic resonance ima
ST-segment elevation acute myocardial infarction.istently and on a large-scale basis have not been established.e are not certain of the best cell type. There is no convincing
vidence to conclude that one cell type is better than another.
here is no evidence that any particular cell type, including
tem cells, is differentiating to an actual cardiomyocyte, and
here is no evidence that cell survival or transdifferentiation
s required to realize benefits on function. Therefore, we are
ertain that cell therapy will meaningfully impact ventricular
unction to a degree that will yield clinically beneficial
esults on heart failure symptoms or mortality. Therefore,
hat we need to avoid is what we have seen before, and
think what we need is careful basic science, realistic
xpectations, and cohesion in clinical studies.
arction in Humans
ion and
Delivery Method of Delivery Result
5–9 days Intracoronary via lumen
of inflated balloon
Decreased infarct size,
improved perfusion,
and wall motion
LVEF unchanged
h stenting
days after
Intracoronary via balloon
catheter to stent site
Increased global LVEF,
reduction in end-
systolic volumes
(6 months  1 yr)
Decreased infarct size
(1 yr)
days after Intracoronary via catheter
and inflated balloon
Increased LVEF (MRI)
tenting
4 days after
Intracoronary via balloon
catheter to stent site
Increased coronary events
Improved perfusion and
LV performance
h stenting
in after
Subcutaneous (10 g/kg
for 6 days)
Preservation of
myocardium
Prevention of cardiac
remodeling
tenting
after MI
Intracoronary Increased LVEF
tenting
after MI
Intracoronary LVEF unchanged
after PCI Intracoronary LVEF unchanged
Decreased infarct size
Increased regional systolic
function
h successful
in 12 h
t
Subcutaneous (10 g/kg
for 5 days)
LVEF unchanged
Infarct size unchanged
derived progenitor cells; G-CSF  granulocyte colony-stimulating factor; LV  left
CI percutaneous coronary intervention; RCT randomized clinical trial; STEMI
able 4. Percutaneous Valve Repair and Replacement
Mitral valve repair
Annuloplasty approaches (coronary sinus)
MitraLife (ev3)
Cardiac dimensions
Viacor
Edwards (JoMed)
Transventricular or transatrial approach
Aortic valve replacement
Edwards
Corevalvel Inf
pulat
ng of
ithin
I wit
1.5
ction
I 4–8
ith s
 1.
ction
I wit
35 m
ction
ith s
days
ith s
days
day
I wit
with
onse
lood-Pulmonary valve replacement
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Fourth Annual ACC International Lecture May 2, 2006:1754–68One thing I would like to emphasize is that I have been
mpressed by the report of Beltramie et al. (66) in Cell.
igure 14, which has been reproduced from their publica-
ion, shows in the myocardium, of 13 cells, 5 are c-Kit
ells (long arrow); c-Kit is an antigen of staminality. Its
xpression is a proof of staminal potential of these cells. In
ther words, these cells are still uncommitted. There are
ight cells expressing MEF2C (short arrow), which is a
ranscription factor expressed early in the myocyte lineage.
hese cells are thus committed early to myocyte lineage.
nd, finally, there is one cell (asterisk), which already
ontains alpha-sarcomeric actin. This cell is engaged in a
ore advanced stage of myocyte lineage. Therefore, the
uestion is, has the myocardium its own resident stem cell?
f the key finding of resident cardiac stem cells, showing
ultilineage capability, is confirmed, it will have a tremen-
ous impact on our future research. Although we are still
ooking at whether stem cells from bone marrow or muscle
re the most appropriate to repair the myocardium, a new
ressing question arose: Is resident cardiac stem cell manip-
lation possible? Can we recolonize scar tissue or its
urrounding with these resident cardiac stem cells?
ERCUTANEOUS VALVE REPAIR AND REPLACEMENT
he last dream (Table 4)! There are two fields of investi-
ation, the mitral valve repair and the aortic valve replace-
ent. The mitral annuloplasty approach is an attempt to
rimp and reshape the mitral annulus through the coronary
inus, taking advantage of the proximity of the coronary
inus with the annulus. An example from Viacor consists of
permanent implant of a device in the coronary sinus,
hich pushes forward the midportion of the posterior leaflet
nd exerts an outward counterforce on the coronary sinus
igure 14. Has the myocardium its own stem cells? Arrows  C-Kit
ells. C-Kit is an antigen of staminality. Its expression is a proof of staminal
otential of these cells. These cells are still uncommitted. Arrowheads 
ells expressing MEF2C. MEF2C is a transcription factor expressed early
n the myocyte lineage. These cells are committed early to myocyte lineage.
Alpha-sarcomeric actin. This cell is engaged in a more advanced stage of
yocyte lineage. Reprinted, with permission, from Beltrami et al. (66).ear the commissure: the result is a reshaping of the mnnulus. The first-in-human was performed by Stephen
llis in Cleveland. There are other quite efficient technol-
gies. The issue with the coronary sinus approach is that the
bility to reduce the annulus can be limited by the calcifi-
ation of the mitral annulus, which can potentially worsen
he leak at the commissure. In addition, these devices can
reate potential pinching of the circumflex artery. Addition-
lly, there are risks of thrombosis, occlusion, or erosion. But,
evertheless, it is worth exploring these techniques.
The edge-to-edge repair of Alfieri, a surgical procedure,
as now been converted into a percutaneous approach by a
ompany called E-valve. The concept consists of a clip,
hich is attached to the two extremities of the mitral valve.
lipping of the two extremities of the mitral valve results in
considerable reduction of the mitral insufficiency. The
fficacy of Vasopressin Antagonism in Heart FailurE:
utcome Study With Tolvaptan (EVEREST) trial has
ncluded 27 such patients.
Donald Baim and his team are currently testing a more
omplex technique, with a transvascular and transventricular
pproach of the posterior annulus using a complex magnetic
uide placement of an implant from the left ventricle.
nitially, a magnetic catheter is advanced in the coronary
inus and another magnetic catheter is advanced behind the
osterior mitral valve to facilitate the attachment of a first
nchoring implant to which a wire is attached. On this wire,
multilumen catheter is slid over. On both sides of the
itral valve, two more anchoring sutures are attached.
inally, the operator puts the sutures under tension, thereby
linching the annulus.
One of the most recent developments in the field is the
ercutaneous aortic valve replacement pioneered by Cribier
t al. (67). There is an antegrade approach through the vena
ava, crossing the interatrial septum, the mitral valve, and
aking a loop and then crossing the aortic valve with the
tented valve from the left ventricle. Rapid pacing (220
eats/min) is used to reduce the flow across the valve during
he balloon deployment of the stented valve. The results are
uite encouraging, with a complete disappearance of the
ortic gradient. The results of REVIVE show an increase of
he aortic valve area from 0.6 cm2 to 1.7 cm2, an improve-
ent in ejection fraction, an improvement in functional
lass, and the disappearance of the gradient.
There is another interesting technology (CoreValve) that
ses a nitinol self-expanding stent containing a tricuspid
alve introduced retrogradely across the aortic valve. Finally,
hambadkone et al. (68) carefully have succeeded with their
ulmonary valve replacement; to date, more than 100
atients have been treated, with no mortality and a 98%
uccess rate. The average duration of the implant is 12.3
onths.
ONCLUSIONS
ore than ever, the field of interventional cardiology is
oving forward. Now, all these novelties described in this
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1767JACC Vol. 47, No. 9, 2006 Serruys
May 2, 2006:1754–68 Fourth Annual ACC International Lectureecture, are they realistic or unrealistic? I will have a very
hort answer to this question. I will tell you what I keep
aying to the fellows in the department: If the future is
nrealistic, it will remain the future; if the future is realistic,
t will soon become the past.
eprint requests and correspondence: Prof. Patrick W. Serruys,
horaxcenter, Ba 583, Dr. Molewaterplein 40, 3015-GDRotterdam,
he Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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